Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer bi13281553 Valeant s Appoints Howard B. Schiller as Chief Financial Officer..

Ancor Acquires WellSpring Pharmaceutical bi13281553 FORT WORTH, Texas -- Ancor Capital Partners pleased to announce the acquisition of WellSpring Pha..

Valeant Pharmaceuticals Reports 2011 Third Quarter Financial Results bi13281553 Valeant s Reports 2011 Third Quarter Financial Results..

Sentinel Capital Partners and Anchor Capital Parnters Acquire WellSpring Phar bi13281553 NEW YORK -- Sentinel Capital Partners, a private equity firm that invests promising lower middle ..

Easton Pharmaceuticals Moves Towards Its Viorra Revenue Projections and Initi bi13281553 TORONTO, ONTARIO--(Marketwire - Oct. 13, 2011) - Easton s (OTC:EAPH), a specialty company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announced today the appointment of Daniel Bagi, MD as consultant to spearhead Viorra regulatory, patent and product launch initiatives Mexico

K-V Pharmaceutical Announces Updated Makena® Performance Metrics bi13281553 ST. LOUIS, Nov. 8, 2011 /PRNewswire/ -- K-V Company (NYSE: KV.A/ KV.B) (the "Company" or "K-V"), today reported updated performance metrics for Makena®, the only U.S. Food & Drug Administration ("FDA") approved product indicated to reduce the risk of preterm birth..

New Issue-Teva Pharmaceutical sells $5 bln debt 6 parts bi13281553 Nov 7 (Reuters) - Teva Finance Company late on Monday sold $5 billion of senior unsecurednotes six parts, said IFR, a Thomson Reuters service. Barclays Capital, BNP Paribas, Citigroup, ..

Raptor Pharmaceutical Corp. to Present at the Lazard Capital Markets 8th Annu bi13281553 NOVATO, Calif. -- Raptor Corp. ("Raptor" or the "Company") , today announced that Ted Daley, President of Raptor present an overview of the Company at the Lazard ..

NPS Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase 3 bi13281553 NPS s, Inc. (NASDAQ: NPSP), a specialty company developing orphan therapeutics for rare gastrointestinal and endocrine ..

Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province i bi13281553 JERSEY CITY, N.J., Nov. 3, 2011 /PRNewswire/ -- Aoxing (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty company focusing on research, development, manufacturing and distribution of narcotic, pain-management, and addiction treatment s, today..

Curaxis Pharmaceutical Corporation Management to Meet With Shareholders bi13281553 RALEIGH, N.C. -- Timothy R. Wright, Chairman and Interim Chief Executive Officer of Curaxis Corporation ("Curaxis" or the "Company') (OTCQB:CURX.PK - News), announced today that the ..

How pharmaceutical companies can help take the 'neglected' out of neglected t bi13281553 Video What do schistosomiasis, cysticercosis, and lymphatic filariasis have common? Besides verging on the unpronounceable, they are all classified as neglected tropical diseases (NTDs). NTDs are a set of diseases ? seventeen, by the World Health Organization?s count ? that collectively affect over a billion people, but have historically []..

Cynapsus Therapeutics Announces Third Quarter 2011 Financial Results and Rece bi13281553 TORONTO, ONTARIO--(Marketwire - Nov. 10, 2011) - Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, today announced results for the nine months ended September 30, 2011. The third quarter of 2011 represents the Company's third reporting period under ..

Ps2 Backup Software - Home